3 stories
Icotrokinra — branded Icotyde — is Johnson & Johnson's oral peptide for moderate-to-severe plaque psoriasis. The drug was approved on the strength of the ICONIC-ADVANCE Phase 3 program, with roughly 70% of patients achieving clear or almost-clear skin by week 16.
One-year data presented at AAD 2026 showed 49% complete clearance at week 52 (close to 60% in adolescents), with no new safety signals reported. The drug is one of the more visible recent oral peptide approvals outside the GLP-1 class — and a useful proof point for oral peptide formulations in inflammatory disease.
Stories here cover trial readouts, AAD presentations, and the broader J&J peptide pipeline. See #psoriasis, #dermatology, and #johnson-johnson.
Oral peptide icotrokinra delivered complete skin clearance through week 52 with a strong safety profile in the ICONIC-ADVANCE trials, presented at the American Academy of Dermatology meeting.
One-year Phase 3 data at AAD 2026 show ICOTYDE (icotrokinra) achieves 49% complete clearance at Week 52, with nearly 60% in adolescents. No new safety signals.
J&J's icotrokinra (Icotyde) approved for moderate-to-severe plaque psoriasis, with ~70% of patients achieving clear or almost clear skin by week 16.